Category: Regulatory

When a hospital procures a digital thermometer, no one expects the same scrutiny that goes into approving a cardiac stent. Both are medical devices — but the risk they carry, and therefore the regulation they need, is worlds apart. India’s medical device regulator, the Central Drugs Standard Control Organisation (CDSCO), captures this difference through a four-tier classification system. Understanding it is the first thing anyone working in the device ecosystem — manufacturer, importer, hospital procurement, or curious patient — needs to know.

What counts as a “medical device”?

Under the Medical Devices Rules, 2017, a medical device is broadly any instrument, apparatus, implant, software, or material intended by its manufacturer to be used for diagnosing, preventing, monitoring, or treating a disease or disorder in humans or animals. It also covers devices intended to investigate, replace, or modify the anatomy or a physiological process, to support or sustain life, to disinfect other medical devices, or to control conception.

That’s a deliberately wide net — and it has to be. A bandage and a robotic surgical system both qualify. The classification system is how CDSCO tells them apart.

The four classes, at a glance

The Medical Devices Rules, 2017 follow the risk-based approach recommended by the Global Harmonization Task Force, sorting devices into Class A (low risk), Class B (low-to-moderate risk), Class C (moderate-to-high risk), and Class D (high risk). The class a device falls into is determined by its intended use, how invasive it is, how long it stays in contact with the body, and whether it is active or passive.

Why classification is the first thing, not a paperwork formality

It is tempting to treat classification as a tick-box exercise — pick a class, move on to the application. In practice, it is the single decision that shapes everything downstream. Classification determines the regulatory pathway, the documentation required, and the approval timeline; an incorrect classification can lead to queries, delays, or outright rejection of the licence application.

It also decides who regulates you. India runs a two-tier licensing system: lower-risk devices are handled by State Licensing Authorities, while higher-risk devices go straight to the central regulator.

Who issues the licence?

The MD-5 licence for Class A and B manufacturing carries a fee of ₹5,000 per licence and ₹500 per distinct device. The MD-9 licence for Class C and D carries ₹50,000 per licence and ₹1,000 per device. Manufacturing licences are valid for five years, with renewal applications required before expiry.

What sits behind every approval, regardless of class

No matter the class, CDSCO expects three pieces of evidence before it grants a licence: that the manufacturer runs a credible quality system (typically ISO 13485:2016, aligned with Schedule V of MDR 2017), that the device itself is well-documented (the Device Master File), and that the facility is fit for purpose (the Plant Master File). What changes with class is not whether these exist, but how deeply CDSCO scrutinises them.

For Class A and B, a Notified Body conducts the audit and the State Licensing Authority issues the licence. For Class C and D, CDSCO’s own auditors inspect the site and the Central Licensing Authority grants the approval. The shift from third-party audit to regulator-led audit is the single biggest jump in the journey from Class B to Class C.

Where IVF devices land

For anyone in assisted reproduction, the classification map matters in very specific ways. IVF culture media, embryo transfer catheters, and ICSI micropipettes typically sit in Class C — they make direct contact with gametes and embryos that will become a pregnancy. Robotic ICSI systems, cryostorage monitoring devices, and lab management software each have their own classification logic depending on whether they touch the biological material, monitor a critical parameter, or simply organise information.

The pattern is consistent: the closer a device sits to the embryo, and the more its failure could compromise a cycle outcome, the higher the class — and the longer and more documentation-heavy the path to market.

Classification is the doorway, not the destination. But walk through the wrong one, and every step that follows costs more time and money than it should. For founders, importers, and clinical leads alike, getting this first decision right is the cheapest insurance the regulatory process offers.